Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» AbbVie
AbbVie
AbbVie Puts Potential $713M on the Line for OSE’s Inflammation Antibody
BioSpace
Wed, 02/28/24 - 11:12 am
AbbVie
OSE Immunotherapeutics
OSE-230
inflammation
monoclonal antibodies
After long road to approval, Teva and Alvotech believe their Humira biosimilar Simlandi may have an edge
Fierce Pharma
Sun, 02/25/24 - 08:57 pm
Teva Pharmaceutical
Alvotech
AbbVie
Humira
biosmilars
AbbVie wraps up $64M oncology, immunology deal with Tentarix
Fierce Biotech
Thu, 02/22/24 - 11:28 am
AbbVie
Tentarix
onoclogy
immunology
AbbVie’s Cerevel deal hits an uncommon roadblock
BioPharma Dive
Wed, 02/21/24 - 11:10 am
AbbVie
Cerevel Therapeutics
M&A
FTC
antitrust
AbbVie CEO Richard Gonzalez to step down, Robert Michael to succeed him
Medical Marketing and Media
Tue, 02/20/24 - 11:39 am
AbbVie
Richard Gonzalez
Pharma CEOs
Robert Michael
AbbVie wraps up its $10.1B buyout of ImmunoGen well ahead of schedule
Fierce Pharma
Mon, 02/12/24 - 11:07 pm
AbbVie
Immunogen
M&A
Top 40 Best-Selling Oncology Drugs in 2023 by 2022 Data
Xtalks
Mon, 02/5/24 - 10:17 am
oncology
cancer
Keytruda
Revlimid
Opdivo
Imbruvica
Darzalex
Merck
Bristol Myers Squibb
AbbVie
Janssen
As Humira plummets, AbbVie dials up Rinvoq and Skyrizi estimates to a combined $27B
Fierce Pharma
Fri, 02/2/24 - 11:58 am
AbbVie
earnings
Humira
Rinvoq
Skyrizi
AbbVie raises 2027 sales forecast for new immunology drugs to $27 billion
Reuters
Fri, 02/2/24 - 11:40 am
AbbVie
earnings
AbbVie invests $223m in Singapore biologics site
Pharmaphorum
Fri, 01/26/24 - 11:13 am
AbbVie
Singapore
biologics
drug manufacturing
Karuna, Cerevel might be just the start of psychiatry drug M&A
BioPharma Dive
Tue, 01/23/24 - 11:17 am
M&A
Karuna Therapeutics
Cerevel Therapeutics
schizophrenia
AbbVie
Bristol Myers Squibb
Two more pharmas practice their Accent, invest in $75M series C round
Fierce Biotech
Tue, 01/23/24 - 10:47 am
Accent Therapeutics
funding
RNA
Bristol Myers Squibb
JNJ
AbbVie
AbbVie’s Humira Maintains Market Dominance Amid Biosimilar Launches: Report
BioSpace
Thu, 01/18/24 - 11:30 am
AbbVie
Humira
biosimilars
Top 5 Life Science Companies Hiring Remote
BioSpace
Thu, 01/18/24 - 11:12 am
remote work
hirings
Takeda
AbbVie
Moderna Therapeutics
Biomarin
CSL Behring
AbbVie-backed Disco gets down with €20M to find new targets for antibody-based therapies
Fierce Biotech
Tue, 01/16/24 - 09:14 am
Disco Pharmaceuticals
AbbVie
venture capital
lung cancer
colorectal cancer
AbbVie expects Botox to maintain market share as competition heats up
Reuters
Wed, 01/10/24 - 06:24 pm
AbbVie
aesthetics
Botox
Evolus
Jeuveau
Revance Therapeutics
Daxxify
AbbVie introduces Produodopa for advanced Parkinson’s in EU
Pharmaceutical Business Review
Wed, 01/10/24 - 09:31 am
AbbVie
Produodopa
Parkinson's Disease
Europe
AbbVie reports data from trial of hidradenitis suppurativa drug
Clinical Trials Arena
Tue, 01/9/24 - 10:01 pm
AbbVie
clinical trials
hidradenitis suppurativa
lutikizumab
The Big Three PBMs’ 2024 Formulary Exclusions: Biosimilar Humira Battles, CVS Health’s Weird Strategy, and the Insulin Shakeup
Drug Channels
Tue, 01/9/24 - 09:41 am
PBMs
formularies
Caremark
Express Scripts
OptumRx
biosimilars
Humira
AbbVie
insulin
All AbbVie's CEO wanted for Christmas was Cerevel—oh, and ImmunoGen, too
Fierce Biotech
Mon, 01/8/24 - 11:30 am
AbbVie
Richard Gonzalez
Cerevel Therapeutics
M&A
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »